Rucaparib (Rubraca): Full FDA-Approved Guide for BRCA-Mutated Prostate Cancer Treatment

　　On December 17,2025,the U.S.Food and Drug Administration(FDA)granted regular approval to rucaparib(brand name Rubraca),a poly(ADP-ribose)polymerase(PARP)inhibitor,for the treatment of adult patients with deleterious BRCA mutation(germline and/or somatic)-associated metastatic castration-resistant prostate cancer(mCRPC).This approval,based on positive results from a pivotal phase III clinical trial,marks a milestone conversion from the accelerated approval granted in 2020 to full regular approval,further consolidating the central role of precision molecular subtyping in the management of advanced prostate cancer,and driving the continuous advancement of prostate cancer treatment towards personalized precision medicine.

　　Drug Basic Information

　　Rucaparib,marketed under the brand name Rubraca,is developed and commercialized by Pharma&GmbH.It is an oral small-molecule PARP inhibitor targeting the DNA damage repair pathway,offering a convenient administration route that supports long-term at-home treatment for patientsFDA Access Data.As a key member of the PARP inhibitor class,rucaparib exerts its anti-tumor effect by interfering with the DNA repair mechanism of tumor cells,enabling selective killing of cancer cells with homologous recombination deficiency(HRD),and serving as an important agent for precision targeted therapy of solid tumors.

　　Mechanism of Action:Precision Anti-Tumor Effect Based on"Synthetic Lethality"

　　The core anti-tumor activity of rucaparib is based on the classic pharmacological principle of"synthetic lethality".The BRCA gene is a key regulator of cellular DNA homologous recombination repair,and deleterious mutations in BRCA directly lead to homologous recombination deficiency in tumor cells,disabling the accurate repair of damaged DNA.PARP protein is a core molecule in the repair of single-strand DNA breaks,and rucaparib blocks the single-strand DNA repair pathway in tumor cells through selective inhibition of PARP activity.

　　On the basis of homologous recombination deficiency caused by BRCA mutations,the blockade of single-strand repair via PARP inhibition results in the failure of both major DNA repair pathways in tumor cells.Massive irreversible DNA damage accumulates continuously,ultimately inducing apoptosis of cancer cells.This mechanism confers high target selectivity of rucaparib to BRCA-mutated tumor cells,enhancing anti-tumor efficacy while minimizing the impact on normal cells,and optimizing the safety window of treatment.

　　Approved Indications and Patient Selection Criteria

　　This full regular approval by the FDA defines clear and strict eligibility criteria to precisely match the patient population that can derive clinical benefit,embodying the core principle of precision medicine:"test first,treat later".Eligible patients must meet all of the following criteriaFDA Access Data:

　　A confirmed diagnosis of metastatic castration-resistant prostate cancer(mCRPC);

　　Confirmed presence of a deleterious BRCA mutation(either germline or somatic);

　　Prior treatment with an androgen receptor pathway inhibitor(ARPI).

　　In addition,the FDA explicitly requires that patients must be tested for BRCA mutation status using an FDA-approved companion diagnostic(CDx)prior to initiating rucaparib treatment,to ensure the precision of treatment and clinical benefit from the source.

　　Pivotal Clinical Evidence:The Phase III TRITON3 Trial

　　The core basis for this approval is the TRITON3 trial(ClinicalTrials.gov identifier:NCT02975934),a randomized,open-label,controlled phase III clinical trial.This study provided high-level evidence-based medical data for the clinical benefit of rucaparib,and served as the key validation required for the conversion from accelerated approval to full regular approvalU.S.Food and Drug Administration.

　　The trial enrolled a total of 405 patients with mCRPC,of whom 302 had BRCA mutations(BRCAm)and 103 had ATM mutations(ATMm).Enrolled patients were randomly assigned to two treatment groups:the rucaparib treatment group,and the treatment of physician’s choice group(including enzalutamide,abiraterone acetate,or docetaxel).All enrolled patients maintained castrate levels of testosterone via medical or surgical castration throughout the trial.

　　Key Efficacy Data

　　The study results showed that the clinical benefit of rucaparib was highly concentrated in patients with BRCA mutations,precisely verifying the necessity of treatment guided by molecular subtyping.

　　In the BRCA-mutated patient population,rucaparib demonstrated a significant progression-free survival benefit:the median radiographic progression-free survival(rPFS)was 11.2 months in the rucaparib group,compared with 6.4 months in the control group,with a hazard ratio(HR)of 0.50.This means rucaparib reduced the risk of disease progression or death by approximately 50%,a result with statistically significant difference,which served as the core evidence supporting this full FDA approval.

　　For overall survival(OS),the median OS was 23.2 months in the rucaparib group and 21.2 months in the control group,with a hazard ratio(HR)of 0.91.Although the difference did not reach the predefined statistical significance,the overall survival trend still supports the clinical benefit of rucaparib treatment.

　　Exploratory analysis of the ATM-mutated subgroup showed that the HR for rPFS was 0.95 and the HR for OS was 1.21 in this population,with no clear clinical benefit observed.This further confirms that the therapeutic value of rucaparib is highly concentrated in patients with BRCA mutations,and re-emphasizes the core necessity of pre-treatment genetic testing and precise molecular subtyping.

　　Safety Profile and Risk Management

　　The overall safety profile of rucaparib is consistent with data from previous clinical studies,with a manageable safety profile and no new unexpected safety signals identified.Key risks should be focused on and managed in a standardized manner during clinical use.

　　The most critical safety risks to monitor during treatment fall into three main categories:First,myelosuppression-related adverse reactions,commonly manifested as anemia,thrombocytopenia,and neutropenia.Regular blood count monitoring is required during clinical use to detect and manage hematological abnormalities in a timely manner with symptomatic treatment.Second,the potential risk of myelodysplastic syndrome(MDS)or acute myeloid leukemia(AML).Continuous hematological monitoring is required during treatment,and permanent discontinuation is mandatory if MDS/AML is confirmed.Third,embryo-fetal toxicity,as the drug can cause severe harm to fetal development.Male and female patients of reproductive potential must use effective contraception during treatment and for a specified period after the last dose.

　　Most treatment-related adverse reactions are mild to moderate,and can be effectively relieved with symptomatic supportive care,dose adjustment,or temporary treatment interruption,with an overall favorable treatment tolerability.

　　Recommended Dosage and Standardized Dosing Guidelines

　　The recommended clinical dose of rucaparib is 600 mg(two 300 mg tablets)taken orally twice daily,with or without food.Treatment should be continued until disease progression or unacceptable toxicity occurs.

　　This oral dosing regimen does not require inpatient infusion,with a fixed administration frequency,providing high treatment convenience for patients,and better supporting treatment adherence and quality of life.In clinical practice,dose adjustments should be made under the guidance of a qualified healthcare professional based on the patient's tolerability and adverse reaction occurrence.Patients should not increase,decrease,or discontinue the dose by themselves.

　　Disease Background and Clinical Therapeutic Significance

　　Metastatic castration-resistant prostate cancer is the end-stage of prostate cancer,characterized by loss of sensitivity to androgen deprivation therapy,continuous disease progression,high incidence of bone and visceral metastases,and poor overall prognosis,with a large unmet clinical treatment need.

　　Although ARPI agents represented by enzalutamide and abiraterone have significantly prolonged the overall survival of these patients,drug resistance is prevalent in clinical practice.Most patients experience disease progression after ARPI treatment,with very limited subsequent treatment options.Precision targeted therapy for specific molecular abnormalities has become a core direction to break through this treatment dilemma.

　　The full FDA approval of rucaparib not only provides a new oral targeted treatment option for patients with BRCA-mutated mCRPC who have received prior ARPI therapy,but also reconfirms the core value of genetic testing and molecular subtyping in the full-course management of prostate cancer.With the continuous development of precision medicine,biomarker-based personalized treatment is becoming the core paradigm for advanced prostate cancer treatment,bringing the hope of long-term survival to more patients.